Clinical Trial Update: Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with erlotinib or sorafenib as first-line therapy in advanced liver cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-09-11